Page 69 - 84_02

113 Mechoulam R, Shvo Y. Hashish-I. The structure of Paula Morales, Pilar Goya, Nadine Jagerovic
Res Commun 2017; 490: 17-21.
cannabidiol. Tetrahedron 1963; 19: 2073–78. 128 Soethoudt M, Grether U, Fingerle J, et al.
Cannabinoid CB2 receptor ligand profiling reveals
114 Ibeas Bih C, Chen T, Nunn AVW, Bazelot M, Dallas biased signalling and off-target activity. Nat Commun
2017; 8: 13958.
M, Whalley BJ. Molecular Targets of Cannabidiol in 129 Laprairie RB, Bagher AM, Denovan-Wright EM.
Cannabinoid receptor ligand bias: implications in the
Neurological Disorders. Neurotherapeutics 2015; 12: central nervous system. Curr Opin Pharmacol 2017;
32: 32–43.
699–730. 130 Laprairie RB, Bagher AM, Kelly MEM, Denovan-
Wright EM. Biased Type 1 Cannabinoid Receptor
115 Pisanti S, Malfitano AM, Ciaglia E, et al. Signaling Influences Neuronal Viability in a Cell
Cannabidiol: State of the art and new challenges for Culture Model of Huntington Disease. Mol Pharmacol
2016; 89: 364–75.
therapeutic applications. Pharmacol Ther 2017; 175: 131 Pupo AS, Duarte DA, Lima V, Teixeira LB, Parreiras-
e-Silva LT, Costa-Neto CM. Recent updates on GPCR
133-50. biased agonism. Pharmacol Res 2016; 112: 49–57.
132 Rankovic Z, Brust TF, Bohn LM. Biased agonism: An
116 Fasinu PS, Phillips S, Elsohly MA, Walker LA. emerging paradigm in GPCR drug discovery.
Bioorganic Med Chem Lett 2016; 26: 241–50.
Current Status and Prospects for Cannabidiol 133 Zhou XE, Melcher K, Xu HE. Understanding the
GPCR biased signaling through G protein and arrestin
Preparations as New Therapeutic Agents. complex structures. Curr Opin Struct Biol 2017; 45:
150–59.
Pharmacotherapy 2016; 36: 781-96. 134 Ibsen MS, Connor M, Glass M. Cannabinoid CB 1 and
CB 2 Receptor Signaling and Bias. Cannabis
117 Lago-Fernandez A, Redondo V, Hernandez-Folgado Cannabinoid Res 2017; 2: 48–60.
L, Figuerola-Asencio L, Jagerovic N. New Methods
@Real Academia Nacional de Farmacia. Spain
for the Synthesis of Cannabidiol Derivatives. In:

Reggio PH, Ed. Cannabinoids and Their Receptors.

London: Elsevier, 2017, pp 237–57.

118 Arnoldi A, Bizzozero N, Merlini L, Ragg E, Rossi

AC. Analogs of cannabinoids. Synthesis of N-

heterocyclic derivatives of olivetol. J Chem Res

Synopses 1983; 1: 107.

119 Scherma M, Satta V, Fratta W, Fadda P. The

endocannabinoid system: Anorexia nervosa and binge

eating disorder. In: Fattore L., Ed. Cannabinoids in

Neurologic and Mental Disease. New York: Elsevier,

2015, pp 389–413.

120 Clinical Trials Cannabinoids.

https://clinicaltrials.gov/ct2/results?term=cannabinoid

s&pg=1 (accessed 28 Sep2017).

121 Picone RP, Kendall D. Minireview: From the Bench,

Toward the Clinic: Therapeutic Opportunities for

Cannabinoid Receptor Modulation. Mol Endocrinol

2015; 29: 801–13.

122 Dhopeshwarkar A, Mackie K. CB2 cannabinoid

receptors as a therapeutic target - What does the future

hold? Mol Pharmacol 2014; 86: 430–37.

123 Vemuri VK, Makriyannis A. Medicinal Chemistry of

Cannabinoids. Clin Pharmacol Ther 2015; 97: 553–

58.

124 Morales P, Hurst DP, Reggio PH. Molecular Targets
of the Phytocannabinoids: A Complex Picture. In:

Kinghorn AD, Gibbons S, Eds. Phytocannabinoids

Unraveling the Complex Chemistry and

Pharmacology of Cannabis sativa. Cham: Springer

International Publishing, 2017, pp 103–31.

125 Morales P, Reggio PH, Jagerovic N. An Overview on
Medicinal Chemistry of Synthetic and Natural

Derivatives of Cannabidiol. Front Pharmacol 2017; 8:

422.

126 Brown KJ, Laun AS, Song Z. Cannabidiol, a novel
inverse agonist for GPR12. Biochem Biophys Res

Commun 2017; 493: 451–54.

127 Laun AS, Song Z-H. GPR3 and GPR6, novel

molecular targets for cannabidiol. Biochem Biophys

184